The EMPEROR clinical trials – Further guidance for today’s clinical practice

shutterstock_1039148917 - image for home page

The current approach to foundational therapy for patients with heart failure has four pillars and use of these four drug classes should be continued for as long as the patient can cope with the regimen

You will learn:

  • Details of current European and American heart failure (HF) guidelines regarding the use of sodium-glucose co-transporter 2 (SGLT-2) inhibitor therapy in patients with our without diabetes
  • Current research increasing our understanding of the possible deleterious clinical implications of withdrawing SGLT-2 inhibitor therapy in patients with chronic HF

To access this module, please register or login: